new-recommended-broker-banner
Scientist in lab

Shares of Sareum Holdings Plc (LON: SAR) today surged 5.88% despite the company not making any major announcements as buyers took control following 2-day sell-off.

The biotech company’s last announcement was on December 3, when it received a £174,000 grant from UK Research & Innovation (UKRI) to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in treating severe cases of  the coronavirus (Covid-19).

Sareum’s shares rallied higher on the news but the rally was followed by a 2-day sell-off, which ended today after the company’s shares rallied higher.

The company’s shares are trading at a major support size, which could explain today’s rally as bulls stepped in and pushed the price higher wresting control away from the bears.

However, today’s rally does not mean that the current downtrend is now over, we need at least a few bullish days before we can say that a new uptrend had begun.

Investors interested in accumulating a position in Sareum may find that the current prices present an excellent opportunity given that the current support zone has been in place since October and is also supported by long-term trends.*

Regardless, Sareum needs a strong positive fundamental trigger that could fuel the next rally, which is yet to happen. The stock had turned lower at the time of publishing underscoring the need for strong fundamental drivers.

*This is not investment advice

Sareum share price

Tradingview chart of Sareum share price 08122020

Sareum shares surged 5.88% today to trade at 1.350p having rallied from Monday’s closing price of 1.275p.

Trade Sareum Shares Now

People who read this also read:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .